BLZ945 is primarily utilized in the field of medical research, particularly in oncology. It serves as a selective inhibitor targeting the colony-stimulating factor 1 receptor (CSF1R), which plays a crucial role in the regulation of macrophages. By inhibiting CSF1R, BLZ945 effectively modulates the tumor microenvironment, reducing the presence of tumor-associated macrophages that support tumor growth and immune evasion. This makes it a valuable tool in studying cancer immunotherapy and exploring potential treatments for various cancers, including glioblastoma and other solid tumors. Additionally, its application extends to understanding the role of macrophages in inflammatory diseases and neurodegenerative conditions, providing insights into therapeutic strategies for these disorders.